This randomized study addressed the role of maintenance bacillus Calmette-Guérin intravesical therapy. Compared to standard induction therapy (6 weekly treatments), the addition of maintenance for 3 years was beneficial for patients with carcinoma in situ and for select patients with Ta or T1 bladder cancer. Median recurrencefree survival time was twice as long in the maintenance arm compared with the no-maintenance arm, and patients had significantly longer worsening-free survival.
Czerniak B, Li L, Chaturvedi V, et al. Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer. 2000; 27:392-402. A model was developed for human urinary bladder cancer progression starting with in situ precursor lesions to invasive carcinoma using whole-organ histologic and genetic mapping. Chromosomes 4, 8, 9, 11, and 17 were assessed for allelic losses. The majority of statistically significant allelic losses (70%) occurred early, in low-grade tumors and in adjacent areas of morphologically normal mucosa. The remaining 30% occurred in the later phases of urothelial neoplasia.
